Business Wire · SMMT · October 23, 2026

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Get the app for more

Explore stock news, insights and company research.